NCT05969925 is a clinical trial of new biomarkers for heart failure in Heart Failure, sponsored by Ahmed Ali Mahny.

Who is sponsoring NCT05969925?

NCT05969925 is sponsored by Ahmed Ali Mahny.

What drugs are being tested in NCT05969925?

Interventions in NCT05969925: new biomarkers for heart failure.

What condition does NCT05969925 study?

NCT05969925 studies Heart Failure.

Is NCT05969925 still recruiting?

NCT05969925 is currently status unknown. Last updated 2 August 2023.

Last reviewed 2023-08-02 · How we verify

NCT05969925

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers of Pediatric Heart Failure

Status unknown Last updated 2 August 2023

What this trial tests

trial testing new biomarkers for heart failure in Heart Failure in 70 participants. Status unknown.

Timeline

1 September 2023

Primary endpoint
2 September 2024

2 September 2024

Quick facts

Lead sponsor	Ahmed Ali Mahny
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	70
Start date	1 September 2023
Primary completion	2 September 2024
Estimated completion	2 September 2024

Drugs / interventions tested

new biomarkers for heart failure

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Ahmed Ali Mahny

Who can join

Adults 1 Month to 16, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Heart failure (HF) is a clinical syndrome where the heart is unable to pump the blood required to meet the metabolic demands of the body. Heart failure in children can result from a variety of structural or functional cardiac disorders with subsequent failure of the ventricles to fill with or eject blood

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05969925 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ahmed Ali Mahny
Last refreshed: 2 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05969925.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing